184 related articles for article (PubMed ID: 27650575)
1. Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.
Ghasemi R; Lazear E; Wang X; Arefanian S; Zheleznyak A; Carreno BM; Higashikubo R; Gelman AE; Kreisel D; Fremont DH; Krupnick AS
Nat Commun; 2016 Sep; 7():12878. PubMed ID: 27650575
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of the cowpox virus-encoded NKG2D ligand OMCP.
Lazear E; Peterson LW; Nelson CA; Fremont DH
J Virol; 2013 Jan; 87(2):840-50. PubMed ID: 23115291
[TBL] [Abstract][Full Text] [Related]
3. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.
Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W
J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects.
Kang TH; Mao CP; He L; Tsai YC; Liu K; La V; Wu TC; Hung CF
PLoS One; 2012; 7(4):e35141. PubMed ID: 22509395
[TBL] [Abstract][Full Text] [Related]
5. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.
Chen Y; Chen B; Yang T; Xiao W; Qian L; Ding Y; Ji M; Ge X; Gong W
Cell Mol Immunol; 2017 Mar; 14(3):293-307. PubMed ID: 26364916
[TBL] [Abstract][Full Text] [Related]
6. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
7. Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D.
Campbell JA; Trossman DS; Yokoyama WM; Carayannopoulos LN
J Exp Med; 2007 Jun; 204(6):1311-7. PubMed ID: 17548517
[TBL] [Abstract][Full Text] [Related]
8. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
9. MICA/IL-12: A novel bifunctional protein for killer cell activation.
Tietje A; Yang X; Yu X; Wei Y
Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Group 2A Expressed on Both Peripheral CD3
Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
[TBL] [Abstract][Full Text] [Related]
11. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
12. In silico modeling identifies CD45 as a regulator of IL-2 synergy in the NKG2D-mediated activation of immature human NK cells.
Mukherjee S; Jensen H; Stewart W; Stewart D; Ray WC; Chen SY; Nolan GP; Lanier LL; Das J
Sci Signal; 2017 Jun; 10(485):. PubMed ID: 28655861
[TBL] [Abstract][Full Text] [Related]
13. Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin.
Campbell JA; Davis RS; Lilly LM; Fremont DH; French AR; Carayannopoulos LN
J Immunol; 2010 Jul; 185(1):28-32. PubMed ID: 20519648
[TBL] [Abstract][Full Text] [Related]
14. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
15. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
16. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
17. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
18. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
19. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
20. Effects of NKG2D haplotypes on the cell-surface expression of NKG2D protein on natural killer and CD8 T cells of peripheral blood among atomic-bomb survivors.
Imai K; Hayashi T; Yamaoka M; Kajimura J; Yoshida K; Kusunoki Y; Nakachi K
Hum Immunol; 2012 Jun; 73(6):686-91. PubMed ID: 22507622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
